Business Description
Tryptamine Therapeutics Ltd
ISIN : AU0000331993
Share Class Description:
ASX:TYP: Ordinary SharesDescription
Tryptamine Therapeutics Ltd is a clinical-stage biotechnology company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. The programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. Its product pipeline includes TRP-8803 (IV-infused psilocin) and TRP-8802 (oral psilocybin).
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.7 | |||||
| Equity-to-Asset | 0.88 | |||||
| Debt-to-Equity | 0.57 | |||||
| Debt-to-EBITDA | -2.45 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 9.44 | |||||
| Beneish M-Score | -3.47 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 28.7 | |||||
| 3-Year EPS without NRI Growth Rate | 9.8 | |||||
| 3-Year FCF Growth Rate | 32.9 | |||||
| 3-Year Book Growth Rate | -41.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 31.65 | |||||
| 9-Day RSI | 51.54 | |||||
| 14-Day RSI | 59.26 | |||||
| 6-1 Month Momentum % | -16.36 | |||||
| 12-1 Month Momentum % | -16.36 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.83 | |||||
| Quick Ratio | 7.83 | |||||
| Cash Ratio | 7.65 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -59.7 | |||||
| Shareholder Yield % | 1.89 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1978.82 | |||||
| Net Margin % | -1693.73 | |||||
| FCF Margin % | -560 | |||||
| ROE % | -115.34 | |||||
| ROA % | -80.57 | |||||
| ROIC % | -164.7 | |||||
| ROC (Joel Greenblatt) % | -91.54 | |||||
| ROCE % | -59.57 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 14.04 | |||||
| PB Ratio | 2.8 | |||||
| Price-to-Tangible-Book | 4.3 | |||||
| EV-to-EBIT | -24.31 | |||||
| EV-to-EBITDA | -87.5 | |||||
| EV-to-Revenue | 214.82 | |||||
| EV-to-FCF | -41.93 | |||||
| Price-to-Net-Current-Asset-Value | 4.3 | |||||
| Price-to-Net-Cash | 4.3 | |||||
| Earnings Yield (Greenblatt) % | -4.11 | |||||
| FCF Yield % | -2.66 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Tryptamine Therapeutics Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | 0.255 | ||
| EPS (TTM) (A$) | -0.037 | ||
| Beta | 1.17 | ||
| Volatility % | 85.29 | ||
| 14-Day RSI | 59.26 | ||
| 14-Day ATR (A$) | 0.00336 | ||
| 20-Day SMA (A$) | 0.0434 | ||
| 12-1 Month Momentum % | -16.36 | ||
| 52-Week Range (A$) | 0.017 - 0.057 | ||
| Shares Outstanding (Mil) | 1,276.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Tryptamine Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Tryptamine Therapeutics Ltd Stock Events
| Event | Date | Price(A$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Tryptamine Therapeutics Ltd Frequently Asked Questions
What is Tryptamine Therapeutics Ltd(ASX:TYP)'s stock price today?
The current price of ASX:TYP is A$0.04. The 52 week high of ASX:TYP is A$0.06 and 52 week low is A$0.02.
When is next earnings date of Tryptamine Therapeutics Ltd(ASX:TYP)?
The next earnings date of Tryptamine Therapeutics Ltd(ASX:TYP) is .
Does Tryptamine Therapeutics Ltd(ASX:TYP) pay dividends? If so, how much?
Tryptamine Therapeutics Ltd(ASX:TYP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers